SIBN saw its Momentum Indicator move above the 0 level on September 21, 2023. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned positive. In of the 85 cases, the stock moved higher in the following days. The odds of a move higher are at .
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where SIBN's RSI Oscillator exited the oversold zone, of 21 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for SIBN just turned positive on August 23, 2023. Looking at past instances where SIBN's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SIBN advanced for three days, in of 309 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 223 cases where SIBN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SIBN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
SIBN broke above its upper Bollinger Band on August 30, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.805) is normal, around the industry mean (24.959). P/E Ratio (0.000) is within average values for comparable stocks, (79.268). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (6.238). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (6.042) is also within normal values, averaging (58.582).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. SIBN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SIBN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a sacroiliac joint medical device company
|MFs / NAME||Price $||Chg $||Chg %|
|T. Rowe Price International Stock|
|GMO Resources III|
|Polen International Growth Investor|
|Copeland Dividend Growth Fund Class C|
|Transamerica Small/Mid Cap Value R6|
A.I.dvisor indicates that over the last year, SIBN has been loosely correlated with NSTG. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if SIBN jumps, then NSTG could also see price increases.